Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.
2.

Sushi Domain Containing 2 (SUSD2) inhibits platelet activation and binding to high-grade serous ovarian carcinoma cells.

Lager TW, Roetman JJ, Kunkel J, Thacker M, Sheets JN, Egland KA, Miles CM, Larson MK, Gubbels JAA.

Platelets. 2018 Dec;29(8):834-837. doi: 10.1080/09537104.2018.1530345. Epub 2018 Oct 18.

PMID:
30335544
3.

Longitudinal autoantibody responses against tumor-associated antigens decrease in breast cancer patients according to treatment modality.

Evans RL, Pottala JV, Nagata S, Egland KA.

BMC Cancer. 2018 Jan 31;18(1):119. doi: 10.1186/s12885-018-4022-5.

4.

SUSD2 promotes tumor-associated macrophage recruitment by increasing levels of MCP-1 in breast cancer.

Hultgren EM, Patrick ME, Evans RL, Stoos CT, Egland KA.

PLoS One. 2017 May 5;12(5):e0177089. doi: 10.1371/journal.pone.0177089. eCollection 2017.

5.

SUSD2 expression in high-grade serous ovarian cancer correlates with increased patient survival and defective mesothelial clearance.

Sheets JN, Iwanicki M, Liu JF, Howitt BE, Hirsch MS, Gubbels JA, Drapkin R, Egland KA.

Oncogenesis. 2016 Oct 24;5(10):e264. doi: 10.1038/oncsis.2016.64.

6.

Classifying patients for breast cancer by detection of autoantibodies against a panel of conformation-carrying antigens.

Evans RL, Pottala JV, Egland KA.

Cancer Prev Res (Phila). 2014 May;7(5):545-55. doi: 10.1158/1940-6207.CAPR-13-0416. Epub 2014 Mar 18.

7.

Multiple functions of sushi domain containing 2 (SUSD2) in breast tumorigenesis.

Watson AP, Evans RL, Egland KA.

Mol Cancer Res. 2013 Jan;11(1):74-85. doi: 10.1158/1541-7786.MCR-12-0501-T. Epub 2012 Nov 6.

9.

Interspecies signaling between Veillonella atypica and Streptococcus gordonii requires the transcription factor CcpA.

Johnson BP, Jensen BJ, Ransom EM, Heinemann KA, Vannatta KM, Egland KA, Egland PG.

J Bacteriol. 2009 Sep;191(17):5563-5. doi: 10.1128/JB.01226-08. Epub 2009 Jun 19.

10.

Status of HER-2 gene amplification in breast cancers from Native American women.

Rieck LD, Pottala JV, Eliason SL, Koch MR, Egland PG, Egland KA.

Cancer Genet Cytogenet. 2008 Nov;187(1):54-6. doi: 10.1016/j.cancergencyto.2008.08.004. No abstract available. Erratum in: Cancer Genet Cytogenet. 2009 Apr 1;190(1):52.

11.

High expression of a cytokeratin-associated protein in many cancers.

Egland KA, Liu XF, Squires S, Nagata S, Man YG, Bera TK, Onda M, Vincent JJ, Strausberg RL, Lee B, Pastan I.

Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5929-34. Epub 2006 Apr 3.

12.

Identification of proangiogenic genes and pathways by high-throughput functional genomics: TBK1 and the IRF3 pathway.

Korherr C, Gille H, Schäfer R, Koenig-Hoffmann K, Dixelius J, Egland KA, Pastan I, Brinkmann U.

Proc Natl Acad Sci U S A. 2006 Mar 14;103(11):4240-5. Epub 2006 Mar 6.

13.

Discovery of the breast cancer gene BASE using a molecular approach to enrich for genes encoding membrane and secreted proteins.

Egland KA, Vincent JJ, Strausberg R, Lee B, Pastan I.

Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1099-104. Epub 2003 Jan 21.

14.
15.
16.

Conversion of the Vibrio fischeri transcriptional activator, LuxR, to a repressor.

Egland KA, Greenberg EP.

J Bacteriol. 2000 Feb;182(3):805-11.

17.

Quorum sensing in Vibrio fischeri: elements of the luxl promoter.

Egland KA, Greenberg EP.

Mol Microbiol. 1999 Feb;31(4):1197-204.

Supplemental Content

Loading ...
Support Center